Sign In
Buy AKBA
$0.97
+0.0333 (+3.56%)
At Close: Jun 03, 2026
Best Penny Stocks To Buy Now? 5 Stocks Under $1 To Watch In April
01:37pm, Thursday, 14'th Apr 2022
Penny stocks under $1 to watch right now. The post Best Penny Stocks To Buy Now?
See Why Does HC Wainwright Maintain Neutral On Akebia Stock
06:38pm, Thursday, 07'th Apr 2022 Benzinga
Akebia Therapeutics Inc (NASDAQ: AKBA) announced three poster presentations at the National Kidney Foundation (NKF) Spring Clinical Meetings 2022.
Poster data demonstrated that overall, vadadustat
Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates
07:16pm, Friday, 01'st Apr 2022 Benzinga
Biopharma stocks are sensitive to a key binary event called the PDUFA date, the date by which the Food and Drug Administration is required to give its verdict on a regulatory application filed with it
Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2022
02:05pm, Thursday, 31'st Mar 2022 Benzinga
Upgrades
Raymond James upgraded the previous rating for Starwood Property Trust Inc (NYSE:STWD) from Outperform to Strong Buy. For the fourth quarter, Starwood Property Trust had an EPS of $1.10, comp
6 Stocks Halted In Wednesday's Session
09:12pm, Wednesday, 30'th Mar 2022 Benzinga
A circuit breaker is an automatic, temporary trading halt on certain securities when the underlying stock is experiencing times of high volatility. It is a measure put in place to help restore and br
FDA Rejects Akebia Therapeutics' Vadadustat For CKD-Associated Anemia
03:42pm, Wednesday, 30'th Mar 2022
The FDA has issued a complete response letter (CRL) to Akebia Therapeutics Inc's (NASDAQ: AKBA) marketing application (NDA) for vadadustat for anemia due to chronic kidney disease (CKD). Vadadus
The Daily Biotech Pulse: Sanofi-IGM Ink Antibody Drug Collaboration; NeoGenomics Sinks On CEO Departure, Q1 Warning; Decision Day For Akebia
11:41am, Tuesday, 29'th Mar 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Pfizer Announces Positive Results From Second Late-Stage Study Of Ulcerative Colitis Drug
Pfizer, Inc.
7 Biotech Stocks With Key Catalysts in March
06:24am, Wednesday, 09'th Mar 2022
These seven stocks have some key catalysts lined up for March with the potential to move their price actions in big ways. The post 7 Biotech Stocks With Key Catalysts in March appeared first on Invest
Key FDA Decisions Soon on Akebia, Bristol-Myers and Novartis Drugs
06:17pm, Monday, 07'th Mar 2022
Do Food and Drug Administration decisions—thumbs up or thumbs down—affect the stock prices of companies seeking drug approvals? We're likely to find out this month as several key drugs are about t
Akebia slips as JPMorgan flags regulatory risk for kidney disease drug
07:54pm, Friday, 04'th Mar 2022 Seeking Alpha
Following back-to-back intraday gains, the shares of commercial-stage biotech, Akebia Therapeutics <> have dropped on Friday after JPMorgan highlighted potential regulatory issues…
3 Penny Stocks To Watch For Your List In March 2022
06:02pm, Thursday, 03'rd Mar 2022 PennyStocks
Penny stocks for your watch list this month.
The post 3 Penny Stocks To Watch For Your List In March 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates
12:08pm, Wednesday, 02'nd Mar 2022 Benzinga
The Food and Drug Administration approval calendar was light in February. Nevertheless, the month saw regulatory nods accorded to some breakthrough therapies.
Agios Pharmaceuticals, Inc.'s (NASDAQ: AG
Akebia Therapeutics (AKBA) Reports Q4 Loss, Tops Revenue Estimates
10:35pm, Tuesday, 01'st Mar 2022 Zacks Investment Research
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -21.21% and 23.61%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock
Akebia Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Business Highlights
09:01pm, Tuesday, 01'st Mar 2022 PR Newswire
CAMBRIDGE, Mass., March 1, 2022 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today reported financial results for the fourth quarter and full-year ended December 31, 2021…
Akebia Therapeutics (AKBA) Reports Q4 Loss, Tops Revenue Estimates
07:10pm, Tuesday, 01'st Mar 2022
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -21.21% and 23.61%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock
